ProCE Banner Activity

MANIFEST-2: Phase III Trial of Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib for JAK Inhibitor–Naive Myelofibrosis

Conference Coverage

Adding the novel BET inhibitor pelabresib to ruxolitinib was associated with significantly greater reductions in splenomegaly and a positive trend toward improved symptoms vs placebo plus ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.